His main research concerns Alzheimer's disease, Pathology, Positron emission tomography, Internal medicine and Neuroscience. The various areas that Alexander Drzezga examines in his Alzheimer's disease study include Multivariate statistics, Dementia, Posterior cingulate and Atrophy. His Pathology study combines topics from a wide range of disciplines, such as Central nervous system disease, Neurology and Neuroimaging.
His Positron emission tomography research is multidisciplinary, incorporating perspectives in Liver metabolism, Cortex and Psma pet. His study explores the link between Internal medicine and topics such as Oncology that cross with problems in Psychiatry, Workflow, Scanner and Medical physics. His Neuroscience research includes themes of Antipsychotic and Positive and Negative Syndrome Scale.
Pathology, Neuroscience, Disease, Internal medicine and Positron emission tomography are his primary areas of study. The Pathology study combines topics in areas such as Neuroimaging and In vivo. His study looks at the relationship between Neuroscience and topics such as Cerebral blood flow, which overlap with Brain mapping.
His Internal medicine research is multidisciplinary, relying on both Cognition, Oncology and Cardiology. His Positron emission tomography study is related to the wider topic of Nuclear medicine. The study incorporates disciplines such as Posterior cingulate, Dementia, Fluorodeoxyglucose, Apolipoprotein E and Atrophy in addition to Alzheimer's disease.
His primary scientific interests are in Neuroscience, Internal medicine, Nuclear medicine, Oncology and Pathology. His work in Neuroscience covers topics such as Disease which are related to areas like Head to head. His Etoposide, Prednisone and Solid tumor study, which is part of a larger body of work in Internal medicine, is frequently linked to Procarbazine and Hazard ratio, bridging the gap between disciplines.
His Nuclear medicine research includes elements of Amyloid pet, Voxel and Receiver operating characteristic. Alexander Drzezga interconnects Tumor stage, 18F-DCFPyL, Neuroimaging and Curative treatment in the investigation of issues within Oncology. Particularly relevant to Neurodegeneration is his body of work in Pathology.
Alexander Drzezga spends much of his time researching Neuroscience, Nuclear medicine, Internal medicine, Resting state fMRI and Positron emission tomography. His work is dedicated to discovering how Neuroscience, Pathology are connected with In vivo, Rat model and Hypermetabolism and other disciplines. His biological study spans a wide range of topics, including Neuroimaging, Voxel, Youden's J statistic, Receiver operating characteristic and Statistical parametric mapping.
His Internal medicine study typically links adjacent topics like Oncology. Alexander Drzezga combines subjects such as Functional magnetic resonance imaging, Cognition and Default mode network with his study of Resting state fMRI. His work carried out in the field of Positron emission tomography brings together such families of science as Cerebral perfusion pressure, Perfusion and Perfusion scanning.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Selective changes of resting-state networks in individuals at risk for Alzheimer's disease
Christian Sorg;Valentin Riedl;Valentin Riedl;Mark Mühlau;Vince D. Calhoun.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias
Lisa Mosconi;Wai H. Tsui;Wai H. Tsui;Karl Herholz;Alberto Pupi.
The Journal of Nuclear Medicine (2008)
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.
Alexander Drzezga;Nicola Lautenschlager;Hartwig Siebner;Matthias Riemenschneider.
European Journal of Nuclear Medicine and Molecular Imaging (2003)
First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses
Alexander Drzezga;Michael Souvatzoglou;Matthias Eiber;Ambros J. Beer.
The Journal of Nuclear Medicine (2012)
Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Alexander Drzezga;Timo Grimmer;Matthias Riemenschneider;Nicola Lautenschlager.
The Journal of Nuclear Medicine (2005)
Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies.
Alexander Drzezga;Ulf Darsow;Rolf-Detlef Treede;Hartwig Siebner.
Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid
Timo Grimmer;Matthias Riemenschneider;Hans Förstl;Gjermund Henriksen.
Biological Psychiatry (2009)
Statistical Brain Mapping of 18F-FDG PET in Alzheimer’s Disease: Validation of Anatomic Standardization for Atrophied Brains
Kazunari Ishii;Frode Willoch;Satoshi Minoshima;Alexander Drzezga.
The Journal of Nuclear Medicine (2001)
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
A. Drzezga;T. Grimmer;G. Henriksen;M. Mühlau.
Comparison of [ 18 F]DCFPyL and [ 68 Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
Markus Dietlein;Carsten Kobe;Georg Kuhnert;Simone Stockter.
Molecular Imaging and Biology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: